Temporal Trends of Infective Endocarditis in North America From 2000 to 2017-A Systematic Review.
North America
epidemiology
incidence
infective endocarditis
injection drug use
mortality
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
01
07
2021
accepted:
21
09
2021
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
1
3
2022
Statut:
epublish
Résumé
The objective of this paper was to examine temporal changes of infective endocarditis (IE) incidence and epidemiology in North America. A systematic review was conducted at Mayo Clinic, Rochester. Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science were searched for studies published between January 1, 2000, and May 31, 2020. Four referees independently reviewed all studies, and those that reported a population-based incidence of IE in patients aged 18 years and older in North America were included. Of 8588 articles screened, 14 were included. Overall, IE incidence remained largely unchanged throughout the study period, except for 2 studies that demonstrated a rise in incidence after 2014. Five studies reported temporal trends of injection drug use (IDU) prevalence among IE patients with a notable increase in prevalence observed. The overall incidence of IE has remained stable among the 14 population-based investigations in North America identified in our systematic review. Standardization of study design for future population-based investigations has been highlighted for use in subsequent systematic reviews of IE.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of this paper was to examine temporal changes of infective endocarditis (IE) incidence and epidemiology in North America.
METHODS
METHODS
A systematic review was conducted at Mayo Clinic, Rochester. Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science were searched for studies published between January 1, 2000, and May 31, 2020. Four referees independently reviewed all studies, and those that reported a population-based incidence of IE in patients aged 18 years and older in North America were included.
RESULTS
RESULTS
Of 8588 articles screened, 14 were included. Overall, IE incidence remained largely unchanged throughout the study period, except for 2 studies that demonstrated a rise in incidence after 2014. Five studies reported temporal trends of injection drug use (IDU) prevalence among IE patients with a notable increase in prevalence observed.
CONCLUSIONS
CONCLUSIONS
The overall incidence of IE has remained stable among the 14 population-based investigations in North America identified in our systematic review. Standardization of study design for future population-based investigations has been highlighted for use in subsequent systematic reviews of IE.
Identifiants
pubmed: 35224128
doi: 10.1093/ofid/ofab479
pii: ofab479
pmc: PMC8864733
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab479Subventions
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7):
pubmed: 28705865
Am J Med Sci. 2021 Dec;362(6):562-569
pubmed: 34418358
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
Emerg Infect Dis. 2020 Mar;26(3):
pubmed: 32091385
Circulation. 2021 May 18;143(20):e963-e978
pubmed: 33853363
Clin Infect Dis. 2000 Apr;30(4):633-8
pubmed: 10770721
Eur J Intern Med. 2016 Nov;35:95-99
pubmed: 27339641
Infection. 2020 Jun;48(3):375-383
pubmed: 32100188
PLoS One. 2013;8(3):e60033
pubmed: 23527296
Glob Heart. 2014 Mar;9(1):131-43
pubmed: 25432123
BMC Med. 2019 Sep 4;17(1):169
pubmed: 31481119
Am J Med. 1994 Mar;96(3):200-9
pubmed: 8154507
J Am Coll Cardiol. 2015 May 19;65(19):2070-6
pubmed: 25975469
Open Forum Infect Dis. 2020 Sep 09;7(10):ofaa414
pubmed: 33094117
Mayo Clin Proc. 2010 May;85(5):422-6
pubmed: 20435834
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
J Am Geriatr Soc. 2009 May;57(5):877-81
pubmed: 19484843
Circulation. 2010 Mar 9;121(9):1141-52
pubmed: 20212293
Can J Cardiol. 2016 Aug;32(8):942-8
pubmed: 26868840
Lancet. 2020 Apr 25;395(10233):1325-1327
pubmed: 32334690
BMJ. 1998 Aug 15;317(7156):424-5
pubmed: 9703519
J Am Coll Cardiol. 2015 Sep 8;66(10):1201-2
pubmed: 26338002
Circulation. 2007 Oct 9;116(15):1736-54
pubmed: 17446442
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
Clin Infect Dis. 2021 May 18;72(10):1767-1781
pubmed: 32270861
Am Heart J. 2015 Oct;170(4):830-6
pubmed: 26386808
Heart. 2000 May;83(5):525-30
pubmed: 10768901
J Am Coll Cardiol. 2015 Nov 10;66(19):2156
pubmed: 26541930
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):569-573
pubmed: 28594786
PLoS One. 2013 Dec 09;8(12):e82665
pubmed: 24349331
Int J Drug Policy. 2018 Jul;57:119-129
pubmed: 29754032
Arch Intern Med. 2009 Mar 9;169(5):463-73
pubmed: 19273776
JAMA. 2005 Jun 22;293(24):3022-8
pubmed: 15972564
J Am Coll Cardiol. 2018 Nov 13;72(20):2443-2454
pubmed: 30409564
J Public Health (Oxf). 2012 Mar;34(1):138-48
pubmed: 21795302
Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:17539447211002687
pubmed: 33784909
Circulation. 2019 Jul 16;140(3):170-180
pubmed: 31023074
J Am Heart Assoc. 2019 Oct;8(19):e012969
pubmed: 31530066
Am J Cardiol. 2019 Aug 1;124(3):430-434
pubmed: 31146890
J Am Coll Cardiol. 2013 Dec 10;62(23):2217-26
pubmed: 23994421
BMC Med. 2020 Apr 2;18(1):84
pubmed: 32238164
JAMA. 2017 Apr 25;317(16):1652-1660
pubmed: 28444279
Chest. 2007 Sep;132(3):1025-35
pubmed: 17873196
Clin Infect Dis. 2020 Oct 23;71(7):e37-e44
pubmed: 31907515
J Infect Dis. 2020 Sep 2;222(Suppl 5):S429-S436
pubmed: 32877563
J Am Heart Assoc. 2020 Mar 17;9(6):e012465
pubmed: 32172645
Syst Rev. 2018 Feb 20;7(1):32
pubmed: 29463298
Mayo Clin Proc. 2020 May;95(5):858-866
pubmed: 31902529